RESULT OF RIKSBANK AUCTIONS GOVERNMENT BONDS
| Auction date | 2023-09-15 |
| Loan | 3104 |
| Coupon | 3.50 % |
| ISIN-code | SE0000556599 |
| Maturity | 2028-12-01 |
| Tendered volume, SEK mln | 150 +/- 150 |
| Total bid volume, SEK mln | 260 |
| Volume sold, SEK mln | 150 |
| Number of bids | 6 |
| Number of accepted bids | 3 |
| Average yield | 1.221 % |
| Lowest yield | 1.187 % |
| Highest accepted yield | 1.245 % |
| % accepted at highest yield | 100.00 |
| Auction date | 2023-09-15 |
| Loan | 3112 |
| Coupon | 0.125 % |
| ISIN-code | SE0008014062 |
| Maturity | 2026-06-01 |
| Tendered volume, SEK mln | 250 +/- 250 |
| Total bid volume, SEK mln | 865 |
| Volume sold, SEK mln | 250 |
| Number of bids | 8 |
| Number of accepted bids | 1 |
| Average yield | 1.329 % |
| Lowest yield | 1.329 % |
| Highest accepted yield | 1.329 % |
| % accepted at highest yield | 100.00 |
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Successful completion of recruitment in NANORAD 2, a Phase 2 Clinical Trial of AGuIX® with whole brain radiation therapy in brain metastasis30.11.2023 18:23:37 CET | Press release
Successful completion of recruitment in NANORAD 2, a Phase 2 Clinical Trial of AGuIX® with whole brain radiation therapy in brain metastasis Recruitment led by Grenoble Alpes University Hospital, driven by strong clinical sites participation and investigator support Topline data expected in Q4 2024 Paris (France), November, 30th 2023 – NH TherAguix a Phase 2 biotech company developing AGuIX®, an innovative nanodrug to improve cancer treatment by radiotherapy, announces the completion of recruitment in its NANORAD 2 Phase 2 clinical trial, randomized, multi-center study assessing safety and efficacy of AGuIX® in combination with whole brain radiation therapy versus whole brain radiation therapy alone, in adult patients with multiple brain metastasis. NANORAD 21 is a prospective randomized (1:1) open label trial with a total of 100 patients recruited in 14 active centers coordinated by Dr Camille Verry (CHUGA, Grenoble-Alpes, France) as principal investigator. This trial combines the rad
Vantiva Confirms its Strong Commitment to Diversity, Equity and Inclusion30.11.2023 18:00:00 CET | Press release
Press release Vantiva Confirms its Strong Commitment to Diversity, Equity and Inclusion: the company joins the CEO Action for Diversity & Inclusion™ Initiative; Vantiva has reduced the gender pay gap to 1% as of October 2023. Paris – November 30, 2023 – Vantiva (Euronext Paris: VANTI - formerly known as Technicolor), a global technology leader providing innovative technologies to Network Service Providers (NSPs) that connect consumers around the world, today announced that Chief Executive Officer Luis Martinez-Amago has joined the CEO Action for Diversity & Inclusion™ program, alongside more than 2,400 other business leaders. Signatories of the collective have already shared more than 1,900+ best-known actions, exchanging tangible learning opportunities and creating collaborative conversations via the initiative’s unified hub, CEOAction.com. By participating in this initiative, Vantiva confirms its commitment to taking steps to provide a working environment that respects different view
BW Energy: Mandatory notifications of trade by primary insiders and close associates30.11.2023 17:30:00 CET | Press release
Mandatory notifications of trade by primary insiders and close associates Reference is made to the announcements on 16 November 2023 and 28 November 2023, whereby BW Offshore Limited announced information relating to dividend payments. Please see the attached notifications of trading for information of transactions concerning primary insiders in BW Energy Limited ("BW Energy") and their close associates in connection with the dividend distribution. Further, reference is also made to the announcement on 30 November 2023, whereby it was announced that BW Group Limited purchased 250,000 shares in BW Energy. Please see the attached notification of trading for information of the transaction concerning primary insiders in BW Energy and their close associates in connection with the share purchase of 250,000 shares. For further information, please contact: Knut R. Sæthre, CFO BW Energy +47 91 11 78 76 ir@bwenergy.no About BW Energy: BW Energy is a growth E&P company with a differentiated strat
International Petroleum Corporation Updated Share Capital30.11.2023 17:30:00 CET | Press release
International Petroleum Corporation (IPC or the Corporation) (TSX, Nasdaq Stockholm: IPCO) reports the following, in accordance with the Swedish Financial Instruments Trading Act: Following the cancellation of 427,400 common shares repurchased by IPC under the normal course issuer bid / share repurchase program, the total number of issued and outstanding common shares of the Corporation is 128,224,820 common shares with voting rights as at November 30, 2023, and IPC holds no common shares in treasury. International Petroleum Corp. (IPC) is an international oil and gas exploration and production company with a high quality portfolio of assets located in Canada, Malaysia and France, providing a solid foundation for organic and inorganic growth. IPC is a member of the Lundin Group of Companies. IPC is incorporated in Canada and IPC’s shares are listed on the Toronto Stock Exchange (TSX) and the Nasdaq Stockholm exchange under the symbol "IPCO". For further information, please contact: Reb
Notice of extraordinary general meeting in IDEX Biometrics on 21 December 202330.11.2023 17:30:00 CET | Press release
IDEX Biometrics ASA will hold an extraordinary general meeting on Thursday 21 December 2023 at 12.00 hours CET as an online meeting. There is no physical attendance option. Shareholders may attend online. by PC, smartphone or tablet. The notice with attendance form will be sent to the shareholders today and is also enclosed in pdf file (links to notice, bilingual, and attendance form, English and Norwegian, below). The extraordinary general meeting will consider and resolve Share consolidationIssuance of convertible loan (ref notice to the market on 7 November 2023)Renewal of the customary authorizations to the board to issue sharesAmendment of the 2023 subscription rights incentive plan The notice of the annual general meeting and the ancillary documents are/will be available at the company's web site, www.idexbiometrics.com, and can be requested from the company at no charge from ir@idexbiometrics.com . For further information contact: Marianne Bøe, Investor Relations E-mail: mariann